Extended-release Naltrexone for Alcohol and Opioid Dependence: a Meta-analysis of Healthcare Utilization Studies

Overview

Journal J Subst Abuse Treat

Specialty Psychiatry

Date 2014 May 24

PMID 24854219

Citations 29

Authors

Daniel M Hartung

Dennis McCarty

Rongwei Fu

Katharina Wiest

Mady Chalk

David R Gastfriend

Affiliations

Soon will be listed here.

Abstract

Through improved adherence, once-monthly injectable extended-release naltrexone (XR-NTX) may provide an advantage over other oral agents approved for alcohol and opioid dependence treatment. The objective of this study was to evaluate cost and utilization outcomes between XR-NTX and other pharmacotherapies for treatment of alcohol and opioid dependence. Published studies were identified through comprehensive search of two electronic databases. Studies were included if they compared XR-NTX to other approved medicines and reported economic and healthcare utilization outcomes in patients with opioid or alcohol dependence. We identified five observational studies comparing 1,565 patients using XR-NTX to other therapies over 6 months. Alcohol dependent XR-NTX patients had longer medication refill persistence versus acamprosate and oral naltrexone. Healthcare utilization and costs was generally lower or as low for XR-NTX-treated patients relative to other alcohol dependence agents. Opioid dependent XR-NTX patients had lower inpatient substance abuse-related utilization versus other agents and $8170 lower total cost versus methadone.

Citing Articles

Follow-up and reasons for extended-release naltrexone discontinuation for alcohol use disorder after hospital initiation.

Martin M, Seraydarian M, Gasper J, DeFries T BMJ Open Qual. 2024; 13(4.

PMID: 39653511 PMC: 11628980. DOI: 10.1136/bmjoq-2024-003113.

Pharmacist-Driven Alcohol Use Disorder Screening May Increase Inpatient Utilization of Extended-Release Naltrexone: A Single Center Pilot Study.

Snyder S, Butala N, Williams A, Kneebusch J Pharmacy (Basel). 2024; 12(1).

PMID: 38392933 PMC: 10892525. DOI: 10.3390/pharmacy12010026.

Clinical Implications of the Relationship Between Naltrexone Plasma Levels and the Subjective Effects of Heroin in Humans.

Castillo F, Harris H, Lerman D, Bisaga A, Nunes E, Zhang Z J Addict Med. 2023; 18(2):110-114.

PMID: 38126709 PMC: 10939966. DOI: 10.1097/ADM.0000000000001247.

Single-dose intravenous ketamine or intramuscular naltrexone for high-utilization inpatients with alcohol use disorder: pilot trial feasibility and readmission rates.

Terasaki D, Loh R, Cornell A, Taub J, Thurstone C Addict Sci Clin Pract. 2022; 17(1):64.

PMID: 36419181 PMC: 9682826. DOI: 10.1186/s13722-022-00345-y.

Scanning Analysis of Sequential Semisolvent Vapor Impact To Study Naltrexone Release from Poly(lactide-co-glycolide) Microparticles.

Garner J, Skidmore S, Hadar J, Park H, Park K, Otte A Mol Pharm. 2022; 19(11):4286-4298.

PMID: 36166409 PMC: 9643650. DOI: 10.1021/acs.molpharmaceut.2c00595.

References

Baser O, Chalk M, Fiellin D, Gastfriend D . Cost and utilization outcomes of opioid-dependence treatments. Am J Manag Care. 2011; 17 Suppl 8:S235-48. View

Rosner S, Hackl-Herrwerth A, Leucht S, Vecchi S, Srisurapanont M, Soyka M . Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev. 2010; (12):CD001867. DOI: 10.1002/14651858.CD001867.pub3. View

Gastfriend D . Intramuscular extended-release naltrexone: current evidence. Ann N Y Acad Sci. 2011; 1216:144-66. DOI: 10.1111/j.1749-6632.2010.05900.x. View

Cornish R, Macleod J, Strang J, Vickerman P, Hickman M . Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK General Practice Research Database. BMJ. 2010; 341:c5475. PMC: 2965139. DOI: 10.1136/bmj.c5475. View

Mertens J, Lu Y, Parthasarathy S, Moore C, Weisner C . Medical and psychiatric conditions of alcohol and drug treatment patients in an HMO: comparison with matched controls. Arch Intern Med. 2003; 163(20):2511-7. DOI: 10.1001/archinte.163.20.2511. View

Schneeweiss S, Avorn J . A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol. 2005; 58(4):323-37. DOI: 10.1016/j.jclinepi.2004.10.012. View

Weisner C, Mertens J, Parthasarathy S, Moore C, Lu Y . Integrating primary medical care with addiction treatment: a randomized controlled trial. JAMA. 2001; 286(14):1715-23. PMC: 3056510. DOI: 10.1001/jama.286.14.1715. View

Harris A, Oliva E, Bowe T, Humphreys K, Kivlahan D, Trafton J . Pharmacotherapy of alcohol use disorders by the Veterans Health Administration: patterns of receipt and persistence. Psychiatr Serv. 2012; 63(7):679-85. DOI: 10.1176/appi.ps.201000553. View

McGlynn E, Asch S, Adams J, Keesey J, Hicks J, DeCristofaro A . The quality of health care delivered to adults in the United States. N Engl J Med. 2003; 348(26):2635-45. DOI: 10.1056/NEJMsa022615. View

10.

Bailey J, Hajjar M, Shoib B, Tang J, Ray M, Wan J . Risk factors associated with antihypertensive medication nonadherence in a statewide Medicaid population. Am J Med Sci. 2012; 348(5):410-5. DOI: 10.1097/MAJ.0b013e31825ce50f. View

11.

Sterne J, Sutton A, Ioannidis J, Terrin N, Jones D, Lau J . Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011; 343:d4002. DOI: 10.1136/bmj.d4002. View

12.

Knudsen H, Abraham A, Roman P . Adoption and implementation of medications in addiction treatment programs. J Addict Med. 2011; 5(1):21-7. PMC: 3045214. DOI: 10.1097/ADM.0b013e3181d41ddb. View

13.

Kranzler H, Stephenson J, Montejano L, Wang S, Gastfriend D . Persistence with oral naltrexone for alcohol treatment: implications for health-care utilization. Addiction. 2008; 103(11):1801-8. PMC: 2652482. DOI: 10.1111/j.1360-0443.2008.02345.x. View

14.

Higgins J, Thompson S . Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11):1539-58. DOI: 10.1002/sim.1186. View

15.

Mattick R, Breen C, Kimber J, Davoli M . Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2003; (4):CD002209. DOI: 10.1002/14651858.CD002209. View

16.

Mark T, Montejano L, Kranzler H, Chalk M, Gastfriend D . Comparison of healthcare utilization among patients treated with alcoholism medications. Am J Manag Care. 2011; 16(12):879-88. PMC: 4160801. View

17.

Weiss R . Adherence to pharmacotherapy in patients with alcohol and opioid dependence. Addiction. 2004; 99(11):1382-92. DOI: 10.1111/j.1360-0443.2004.00884.x. View

18.

Knudsen H, Roman P . Financial factors and the implementation of medications for treating opioid use disorders. J Addict Med. 2012; 6(4):280-6. PMC: 3492536. DOI: 10.1097/ADM.0b013e318262a97a. View

19.

Sullivan L, Tetrault J, Braithwaite R, Turner B, Fiellin D . A meta-analysis of the efficacy of nonphysician brief interventions for unhealthy alcohol use: implications for the patient-centered medical home. Am J Addict. 2011; 20(4):343-56. DOI: 10.1111/j.1521-0391.2011.00143.x. View

20.

Lee J, Grossman E, DiRocco D, Truncali A, Hanley K, Stevens D . Extended-release naltrexone for treatment of alcohol dependence in primary care. J Subst Abuse Treat. 2010; 39(1):14-21. DOI: 10.1016/j.jsat.2010.03.005. View